Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used
<b>Background/Objectives</b>: In this ongoing, multicenter, global cohort observational study, phenotypes of headaches after COVID-19 vaccination were directly compared between different vaccines. <b>Methods</b>: Phenotypes of postvaccinal headache were recorded in 18,544 par...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/2/113 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850229656692719616 |
|---|---|
| author | Carl Hartmut Göbel Axel Heinze Katja Heinze-Kuhn Sarah Karstedt Mascha Morscheck Lilian Tashiro Anna Cirkel Qutyaba Hamid Rabih Halwani Mohamad-Hani Temsah Malte Ziemann Siegfried Görg Thomas Münte Hartmut Göbel |
| author_facet | Carl Hartmut Göbel Axel Heinze Katja Heinze-Kuhn Sarah Karstedt Mascha Morscheck Lilian Tashiro Anna Cirkel Qutyaba Hamid Rabih Halwani Mohamad-Hani Temsah Malte Ziemann Siegfried Görg Thomas Münte Hartmut Göbel |
| author_sort | Carl Hartmut Göbel |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: In this ongoing, multicenter, global cohort observational study, phenotypes of headaches after COVID-19 vaccination were directly compared between different vaccines. <b>Methods</b>: Phenotypes of postvaccinal headache were recorded in 18,544 participants. The study was launched immediately after the start of the global COVID-19 vaccination campaign on 12 January 2021 and continued until 1 August 2023. Specific aspects of headaches and related variables were collected via an online questionnaire. The clinical headache characteristics of patients vaccinated with the Comirnaty (BioNTech), Jcovden (Johnson & Johnson), Sputnik V (Gamelaya), Covilo (Sinopharm), Spikevax (Moderna), Vaxzevria (AstraZeneca), and Convidecia (CanSino Biologics) vaccines were investigated. <b>Results</b>: Across all vaccines, the median and mean latency of headache onset after vaccine administration were 12 h and 23.3 h, respectively. The median and mean headache duration were 12 h and 23.3 h, respectively. When the nonreplicating viral vector vaccine Sputnik V was used, headaches occurred the fastest, with a latency of 17 h. The latencies for the Vaxzevria and Convidecia nonreplicating viral vector vaccines were 14.9 h and 19.1 h, respectively. The Covilo inactivated whole-virus vaccine had a latency of 20.5 h. The latencies of the mRNA-based Comirnaty and Spikevax vaccines were 26.0 h and 22.02 h, respectively. Analysis of variance revealed no significant differences in the mean duration of postvaccinal headache for the vaccines tested. Compared with the Comirnaty, Covilo, and Vaxzevria vaccines, the Spikevax vaccine induced significantly greater headache intensities. Vaxzevria was associated with a significantly higher frequency of concomitant symptoms than the other vaccines. <b>Conclusions</b>: The phenotype of postvaccinal headache can vary significantly between vaccines. These results have clinical implications for differentiating between postvaccinal headache and other primary and secondary headaches. This knowledge is clinically relevant in differentiating life-threatening vaccination complications, such as thrombotic syndromes, which are also associated with headaches. Based on these results, new diagnostic criteria for postvaccinal headaches can be developed. |
| format | Article |
| id | doaj-art-92e5e63bfef34667bdf0bee28b4535f5 |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-92e5e63bfef34667bdf0bee28b4535f52025-08-20T02:04:07ZengMDPI AGVaccines2076-393X2025-01-0113211310.3390/vaccines13020113Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine UsedCarl Hartmut Göbel0Axel Heinze1Katja Heinze-Kuhn2Sarah Karstedt3Mascha Morscheck4Lilian Tashiro5Anna Cirkel6Qutyaba Hamid7Rabih Halwani8Mohamad-Hani Temsah9Malte Ziemann10Siegfried Görg11Thomas Münte12Hartmut Göbel13Kiel Migraine and Headache Centre, 24149 Kiel, GermanyKiel Migraine and Headache Centre, 24149 Kiel, GermanyKiel Migraine and Headache Centre, 24149 Kiel, GermanyKiel Migraine and Headache Centre, 24149 Kiel, GermanyKiel Migraine and Headache Centre, 24149 Kiel, GermanyKiel Migraine and Headache Centre, 24149 Kiel, GermanyKiel Migraine and Headache Centre, 24149 Kiel, GermanySharjah Institute of Medical Research, University of Sharjah, Sharjah 26666, United Arab EmiratesSharjah Institute of Medical Research, University of Sharjah, Sharjah 26666, United Arab EmiratesCollege of Medicine, King Saud University, Riyadh 12373, Saudi ArabiaInstitute of Transfusion Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, GermanyInstitute of Transfusion Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, GermanyDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, GermanyKiel Migraine and Headache Centre, 24149 Kiel, Germany<b>Background/Objectives</b>: In this ongoing, multicenter, global cohort observational study, phenotypes of headaches after COVID-19 vaccination were directly compared between different vaccines. <b>Methods</b>: Phenotypes of postvaccinal headache were recorded in 18,544 participants. The study was launched immediately after the start of the global COVID-19 vaccination campaign on 12 January 2021 and continued until 1 August 2023. Specific aspects of headaches and related variables were collected via an online questionnaire. The clinical headache characteristics of patients vaccinated with the Comirnaty (BioNTech), Jcovden (Johnson & Johnson), Sputnik V (Gamelaya), Covilo (Sinopharm), Spikevax (Moderna), Vaxzevria (AstraZeneca), and Convidecia (CanSino Biologics) vaccines were investigated. <b>Results</b>: Across all vaccines, the median and mean latency of headache onset after vaccine administration were 12 h and 23.3 h, respectively. The median and mean headache duration were 12 h and 23.3 h, respectively. When the nonreplicating viral vector vaccine Sputnik V was used, headaches occurred the fastest, with a latency of 17 h. The latencies for the Vaxzevria and Convidecia nonreplicating viral vector vaccines were 14.9 h and 19.1 h, respectively. The Covilo inactivated whole-virus vaccine had a latency of 20.5 h. The latencies of the mRNA-based Comirnaty and Spikevax vaccines were 26.0 h and 22.02 h, respectively. Analysis of variance revealed no significant differences in the mean duration of postvaccinal headache for the vaccines tested. Compared with the Comirnaty, Covilo, and Vaxzevria vaccines, the Spikevax vaccine induced significantly greater headache intensities. Vaxzevria was associated with a significantly higher frequency of concomitant symptoms than the other vaccines. <b>Conclusions</b>: The phenotype of postvaccinal headache can vary significantly between vaccines. These results have clinical implications for differentiating between postvaccinal headache and other primary and secondary headaches. This knowledge is clinically relevant in differentiating life-threatening vaccination complications, such as thrombotic syndromes, which are also associated with headaches. Based on these results, new diagnostic criteria for postvaccinal headaches can be developed.https://www.mdpi.com/2076-393X/13/2/113coronavirus disease 2019COVID-19SARS-CoV-2 virusvaccinationcomplicationsheadache |
| spellingShingle | Carl Hartmut Göbel Axel Heinze Katja Heinze-Kuhn Sarah Karstedt Mascha Morscheck Lilian Tashiro Anna Cirkel Qutyaba Hamid Rabih Halwani Mohamad-Hani Temsah Malte Ziemann Siegfried Görg Thomas Münte Hartmut Göbel Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used Vaccines coronavirus disease 2019 COVID-19 SARS-CoV-2 virus vaccination complications headache |
| title | Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used |
| title_full | Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used |
| title_fullStr | Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used |
| title_full_unstemmed | Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used |
| title_short | Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used |
| title_sort | comparison of phenotypes of headaches after covid 19 vaccinations differentiated according to the vaccine used |
| topic | coronavirus disease 2019 COVID-19 SARS-CoV-2 virus vaccination complications headache |
| url | https://www.mdpi.com/2076-393X/13/2/113 |
| work_keys_str_mv | AT carlhartmutgobel comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT axelheinze comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT katjaheinzekuhn comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT sarahkarstedt comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT maschamorscheck comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT liliantashiro comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT annacirkel comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT qutyabahamid comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT rabihhalwani comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT mohamadhanitemsah comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT malteziemann comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT siegfriedgorg comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT thomasmunte comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused AT hartmutgobel comparisonofphenotypesofheadachesaftercovid19vaccinationsdifferentiatedaccordingtothevaccineused |